Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation

AIDS Patient Care and STDs

Volumn 21, Issue 1, 2007, Pages 1-3

  Gervasoni, Cristina ^a   Vigano, Ottavia ^a   Grinelli, Erika ^a   Ortu, Massimiliano ^a   Galli, Massimo ^a   Rusconi, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CERVICAL LYMPHADENOPATHY; COMBINATION CHEMOTHERAPY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG REEXPOSURE; DRUG WITHDRAWAL; FATIGUE; FEVER; GENERALIZED EDEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MALAISE; MALE; MYALGIA; PATIENT MONITORING; PRURITUS; RASH; SIDE EFFECT; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; OXAZINES; RNA, VIRAL;

EID: 33846783084     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0056     Document Type: Article

References (11)

1. Anderson AM, Bartlett JA. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. Expert Rev Anti Infect Ther 2005;3:871-883.
2. James A, Johann-Liang R. Increased rate and severity of abacavir-associated hypersensitivity reaction in randomised controlled clinical trials [Abstract 835]. In: Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA: 2005.
3. Loeliger AE, Steel H, McGuirk S, et al. The abacavir hypersensitivity reaction and interruptions in therapy. AIDS 2001;15:1325-1326.
4. El-Sahly HM. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient. AIDS 2004;18:359-360.
5. Berenguer J, Padilla B, Estrada V, et al. Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. AIDS 2002;16:1299-1301.
6. Hawkins T. Appearance-related side effects of HIV-1 treatment. AIDS Patient Care and STDs 2006;20:6-18.
7. Goedken AM, Herman RA. Once-daily abacavir in place of twice-daily administration. Ann Pharmacother 2005;39:1302-130-8.
8. Sosa N, Hill-Zabala C, Dejesus E, et al. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J Acquir Immune Defic Syndr 2005;40:422-427.
9. Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: Rresults of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005;38:417-425.
10. Clay PG. The abacavir hypersensitivity reaction: A review. Clin Ther 2002;4:1502-1514.
11. Martin A, Nolan D, Almeida CA, et al. Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics 2006;7:15-23.